 cultures.){kind=link}
MilliporeSigma, has announced a strategic partnership with Promega Corporation to co-develop new assay technologies that enable real-time monitoring of cellular activity within three-dimensional (3D) cultures. The collaboration is designed to accelerate drug screening and discovery by combining the companies’ complementary scientific capabilities.
Under the agreement, MilliporeSigma will contribute its expertise in organoid systems and synthetic chemistry, while Promega brings its assay development and bioluminescent reporter technologies, including its widely used NanoLuc® and HiBiT systems. The joint effort focuses on creating innovative reporter assays that can dynamically track biological processes inside 3D organoid models.
This partnership with Promega shows what is possible when two companies with a shared commitment to science join forces. By combining our organoid expertise with Promega’s advanced reporter technology, we aim to enable high throughput screening that helps researchers identify safer and more effective drug candidates for complex diseases such as cancer—and do it faster than ever before.
Anand Nambiar, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany
In addition to the co-development initiative, the companies have signed a separate agreement to explore the combination of MilliporeSigma’s Duolink® proximity ligation technology with Promega’s HiBiT tagging system. This integration could yield new workflows for probing protein–protein interactions within living cells.
Collaborating with MilliporeSigma allows us to push the boundaries of drug discovery. By combining our technological strengths, we are helping to create more relevant and accessible models for drug discovery, with the goal of enabling new insights and eventually better outcomes for patients.
Tom Livelli, VP, Life Sciences Products & Services at Promega Corporation
The Promega collaboration builds on MilliporeSigma’s broader strategy to expand its leadership in next-generation biology. Earlier this year, the company strengthened its position in the organoid field through the acquisition of HUB Organoids B.V., a pioneer in organoid model development and screening technologies. That acquisition provided access to HUB’s foundational patents and high-throughput model generation capabilities, bolstering MilliporeSigma’s toolkit for translational research.